Lucid Diagnostics Esophageal Precancer Test Receives Positive Data in Clinical Validation Study
Lucid Diagnostics announced that a prospective VA screening study demonstrated strong performance of its EsoGuard Esophageal DNA test.
Read MorePosted by Andy Lundin | Mar 21, 2024 | Gastrointestinal Infections |
Lucid Diagnostics announced that a prospective VA screening study demonstrated strong performance of its EsoGuard Esophageal DNA test.
Read MorePosted by Andy Lundin | Jan 2, 2024 | Diabetes & Metabolic Diseases, Womens Health |
A new study evaluated the diagnostic value of certain markers before or at the time of screening for gestational diabetes mellitus.
Read MorePosted by Andy Lundin | Dec 5, 2023 | Cancer |
UCLA Researchers received $9.1 million in grant funding from the National Cancer Institute to advance liquid biopsy tech for cancer detection.
Read MorePosted by Chris Wolski | Nov 22, 2023 | Disease States |
Metabolic dysfunction-associated steatotic liver disease is estimated to affect about 32.4% of the world’s population.
Read MorePosted by Andy Lundin | Oct 31, 2023 | Cardiovascular |
Next-gen cardiometabolic biomarkers will aid earlier detection of risk factors for obesity, diabetes, and heart disease in children.
Read More